Although this study did not consider placebo effect and has high IPSS baseline scores , this study clarifies that low-dose tamsulosin has generally positive effect and safety in treatment of LUTS and could be a suitable option as an initial treatment , especially for patients with low body mass index , as is typical of Asian people
PURPOSE In Asian countries , low-dose tamsulosin ( 0.2 mg ) is used widely but this dose has been less popular than 0.4 mg tamsulosin or other types of alpha blockers .
The aim of this study was to investigate the efficacy and safety of low-dose tamsulosin by systematic review and meta- analysis .
Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled, Open-Label Non-Inferiority Study
Purpose To compare the efficacy and safety of Sulosin D ( PACIFICPHARMA , Korea ) and Harnal D ( ASTELLAS PHARMA KOREA , Korea ) in treating patients with lower urinary tract symptoms associated with benign prostatic hyperplasia ( BPH ) . Material s and Methods This r and omized , controlled , open-label , multicenter non-inferiority study was conducted at four sites in Korea . We r and omly assigned 123 patients with an International Prostate Symptom Score ( IPSS ) ≥12 to receive either Sulosin D or Harnal D treatment for 8 weeks . The primary outcome was the mean change in IPSS from baseline to endpoint . Secondary outcomes were the mean change from baseline to endpoint in IPSS quality of life subscores , maximum uroflowmetry ( Qmax ) , and post-voiding residuals ( PVR ) . Results In all , 123 patients were r and omly assigned ( 60 Sulosin D and 63 Harnal D ) . The changes in the total IPSS from baseline in the Sulosin D- and Harnal D-treated groups were -4.97 and -4.03 , respectively . There were significant decreases compared with baseline in both groups . The mean difference ( Sulosin D - Harnal D ) was -0.91 ( with a two-sided 90 % confidence interval ) , inferring that Sulosin D was not inferior to Harnal D. The mean changes in the IPSS subscore , Qmax , and PVR from baseline were comparable between the groups ( both p>0.05 ) . During the treatment periods , the incidence of adverse events was 23.33 % and 34.92 % in the Sulosin D and Harnal D groups , respectively ( p=0.1580 ) . Conclusions We demonstrate the non-inferiority of Sulosin D to Harnal D in patients with lower urinary tract symptoms associated with BPH
Although this study did not consider placebo effect and has high IPSS baseline scores , this study clarifies that low-dose tamsulosin has generally positive effect and safety in treatment of LUTS and could be a suitable option as an initial treatment , especially for patients with low body mass index , as is typical of Asian people
PURPOSE In Asian countries , low-dose tamsulosin ( 0.2 mg ) is used widely but this dose has been less popular than 0.4 mg tamsulosin or other types of alpha blockers .
The aim of this study was to investigate the efficacy and safety of low-dose tamsulosin by systematic review and meta- analysis .